HomeProductsBuilding BlocksOrganic Building BlocksBenzene CompoundsReparixin
Chemical structure of CAS 266359-83-5

Reparixin

In Stock•Starting at $21 for 1 mg•Purity ≥ 99%
CAS No.266359-83-5
MDL No.MFCD18633292
MFC14H21NO3S
MW283.39
InChI KeyKQDRVXQXKZXMHP-LLVKDONJSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
1 mg99%$21In Stock
5 mg99%$76In Stock
10 mg99%$148In Stock
25 mg99%$221In Stock
50 mg99%$438In Stock
100 mg99%$641In Stock
250 mg99%$1202In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Reparixin is a monoterpenoid.

CAS No.266359-83-5
Product NameReparixin

Biological Targets

CXCR1·CXCR2

Associated Conditions

type 1 diabetes mellitus·COVID-19·ischemia reperfusion injury·breast cancer·chronic pancreatitis·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.

Breast cancer research : BCR • Vol. 22, Issue 1 • 2020
PMID: 32434589PMC: PMC7238734DOI: 10.1186/s13058-020-01294-7

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes.

Diabetes care • Vol. 43, Issue 4 • 2020
PMID: 32019854PMC: PMC7876579DOI: 10.2337/dc19-1480

Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury.

Proceedings of the National Academy of Sciences of the United States of America • Vol. 101, Issue 32 • 2004
PMID: 15282370PMC: PMC511013DOI: 10.1073/pnas.0402090101

Documentation

Similar Products